Disc Medicine (NASDAQ:IRON) COO Sells $1,287,764.28 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 18,612 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $69.19, for a total transaction of $1,287,764.28. Following the completion of the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,758,677.56. This represents a 25.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Disc Medicine Trading Up 1.0%

NASDAQ IRON traded up $0.73 during trading on Thursday, hitting $70.94. 1,562,335 shares of the company’s stock traded hands, compared to its average volume of 584,908. The stock has a fifty day moving average of $68.44 and a two-hundred day moving average of $71.93. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The firm has a market cap of $2.71 billion, a P/E ratio of -10.72 and a beta of 0.93. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, sell-side analysts expect that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on IRON shares. Wells Fargo & Company upped their price objective on shares of Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Wedbush restated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Truist Financial dropped their price objective on Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Finally, Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $105.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares in the last quarter. BVF Inc. IL bought a new stake in shares of Disc Medicine during the 4th quarter valued at $51,616,000. Jennison Associates LLC purchased a new stake in shares of Disc Medicine in the 4th quarter worth about $42,252,000. Perceptive Advisors LLC purchased a new stake in shares of Disc Medicine in the 4th quarter worth about $35,794,000. Finally, RA Capital Management L.P. increased its stake in shares of Disc Medicine by 25.3% in the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after acquiring an additional 399,026 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.